Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the unique healthcare needs and disparities faced by transgender individuals, highlighting the importance of cultural competency and skills in providers, but reports no new clinical findings.

This study found that physician knowledge of thromboembolism risk associated with cyproterone acetate/ethinylestradiol was generally high, although it varied for complex or less common topics.

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

This case report suggests that dutasteride may be a potential cause of cerebral venous thrombosis, as observed in a 25-year-old male presenting with headache and diplopia that improved after discontinuing the drug.

This review discusses the promising role of JAK inhibitors in managing alopecia areata, reporting significant hair regrowth and acceptable safety profiles but noting the need for further research on dosing and long-term safety.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This correspondence suggests that while patients with Raynaud phenomenon may develop connective tissue disorders, physicians should consider this possibility without assuming for certain that progression will occur.

Drug addicts often have scars, skin color changes, blocked veins, and bruising, with severe ulcers from barbiturate injections.

In this study, pegylated interferon alfa-2b injections led to local cutaneous reactions, including cutaneous necrosis, in patients with hepatitis C and chronic myelocytic leukemia, requiring dose modifications or treatment withdrawal in some cases.

This letter challenges Dr. Dubois' statement that nearly all patients with Raynaud phenomenon will develop a systemic disorder, arguing that many experience it without progressing to serious disease.

This retrospective pharmacovigilance study identified 34 drugs, including finasteride and dutasteride, that may be associated with sexual dysfunction, with a higher risk observed in males aged 31-45.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

This case report documents the first known instance of heparin necrosis linked to tinazaparin, indicating that low-molecular-weight heparin may still cause serious side effects like conventional heparin.

This study found that patients with vitiligo in the United States had higher rates of autoimmune conditions, infections, and skin cancer compared to matched controls, with higher vitiligo prevalence in Asian and Hispanic populations.

This study analyzed adverse event reports from the FDA database and found that drugs such as immunomodulatory agents, monoclonal antibodies, minoxidil, contraceptives, and anti-TNF drugs are frequently associated with hair loss, suggesting guidance for dermatologists in identifying common medications linked to alopecia.

This study analyzed post-marketing data from the U.S. FDA Adverse Event Reporting System and identified both known and new safety concerns for Avacopan, an anti-neutrophil cytoplasmic antibodies-associated vasculitis treatment, emphasizing the need for monitoring during early treatment stages.

This study found that patients with alopecia areata had a higher incidence rate of herpes simplex infection compared to matched individuals without the condition.

This case report describes a 30-year-old man's scleroderma-like skin changes and segmental thrombosis in the left leg, along with elevated blood sugar and advised weight management and limb care.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

In this study, tofacitinib showed a mixed response in treating refractory alopecia areata, with some patients experiencing complete or partial hair regrowth and others showing no response, particularly those with alopecia universalis.

This study conducted a large-scale comparison using FAERS data to assess the post-marketing safety profiles of spironolactone, eplerenone, and finerenone, finding unique adverse event patterns for each drug and highlighting the need for personalized safety monitoring and further investigation in other pharmacovigilance databases.

This review examines AAS-related deaths and finds that anabolic-androgenic steroid abuse may lead to severe cardiac abnormalities, contributing to fatal arrhythmias and sudden cardiac death in young athletes and bodybuilders.

This study found that oral minoxidil is associated with a higher proportional reporting of several cardiovascular adverse events compared to topical minoxidil in spontaneous FDA reports, but these signals should be interpreted as hypothesis-generating rather than evidence of clinical safety.

This review highlights the significant impact of cutaneous and oral mucosal adverse events on patients undergoing breast cancer treatment, emphasizing the need for early detection and comprehensive management to maintain treatment adherence and enhance patient care.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

This congress summary highlights the COMEF 2023 event, which focused on medical ethics, education, and health through discussions with the theme "Learn, practice, excel," but reports no new research findings.

This study identified disproportionate reporting of several serious unknown or less documented adverse events associated with biologics for severe asthma, suggesting the need for further safety assessments.

This abstract describes a program with various presentations and events focused on Canadian excellence in rheumatology but reports no new research findings.